14.55
price down icon2.48%   -0.37
pre-market  プレマーケット:  14.50   -0.05   -0.34%
loading
前日終値:
$14.92
開ける:
$14.78
24時間の取引高:
8.64M
Relative Volume:
1.48
時価総額:
$2.03B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-3.8023
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
+12.88%
1か月 パフォーマンス:
+6.44%
6か月 パフォーマンス:
+59.54%
1年 パフォーマンス:
+62.39%
1日の値動き範囲:
Value
$13.54
$14.92
1週間の範囲:
Value
$11.81
$15.00
52週間の値動き範囲:
Value
$7.95
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1107)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
14.55 2.08B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
453.17 114.33B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
614.73 64.47B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
878.49 54.99B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
281.90 38.42B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
156.58 34.03B 742.00K -1.37B -1.07B -7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Jun 16, 2026

Canaccord reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada

Jun 16, 2026
pulisher
Jun 16, 2026

BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $19 - Moomoo

Jun 16, 2026
pulisher
Jun 16, 2026

Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR) - The Globe and Mail

Jun 16, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results - Insider Monkey

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus - TechStock²

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics jumps after additional Phase 3 HAE data and peer-reviewed publication reinforce lonvo-z outlook - Quiver Quantitative

Jun 15, 2026
pulisher
Jun 15, 2026

Why is Intellia Therapeutics stock surging today? By Investing.com - Investing.com Canada

Jun 15, 2026
pulisher
Jun 15, 2026

Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics | 8-K: Current report - Moomoo

Jun 15, 2026
pulisher
Jun 15, 2026

NTLA Reiterated by Wedbush -- Price Target Maintained at $12.00 - GuruFocus

Jun 15, 2026
pulisher
Jun 15, 2026

NTLA Reiterated by Citizens -- Price Target Maintained at $30 - GuruFocus

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics options trading jumps to 7,041 contracts - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com - Investing.com India

Jun 15, 2026
pulisher
Jun 15, 2026

Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9 - Moomoo

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Benzinga

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Reports Strong Phase 3 Results for lonvo-z, 87% fewer monthly attacks; BLA rolling, U.S. launch H1 2027 - TradingView

Jun 15, 2026
pulisher
Jun 15, 2026

Phase 3 HAELO data support Intellia (NTLA) lonvo-z as potential one-time therapy - Stock Titan

Jun 15, 2026
pulisher
Jun 15, 2026

Why is NTLA stock jumping 5% premarket today? - MSN

Jun 15, 2026
pulisher
Jun 15, 2026

H.C. Wainwright reiterates Intellia stock rating on positive trial data - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

H.C. Wainwright reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada

Jun 15, 2026
pulisher
Jun 15, 2026

Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter

Jun 15, 2026
pulisher
Jun 15, 2026

NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus

Jun 15, 2026
pulisher
Jun 15, 2026

Citizens reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria

Jun 15, 2026
pulisher
Jun 15, 2026

Citizens reiterates Intellia stock rating on positive trial data - Investing.com

Jun 15, 2026
pulisher
Jun 15, 2026

William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating - Moomoo

Jun 15, 2026
pulisher
Jun 15, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Jun 15, 2026
pulisher
Jun 15, 2026

Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN

Jun 15, 2026
pulisher
Jun 14, 2026

Intellia Therapeutics (NTLA) Reports Promising Phase 3 Trial Res - GuruFocus

Jun 14, 2026
pulisher
Jun 14, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Jun 14, 2026
pulisher
Jun 13, 2026

Intellia presents Phase 3 results for HAE gene therapy lonvo-z - Investing.com UK

Jun 13, 2026
pulisher
Jun 13, 2026

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics

Jun 13, 2026
pulisher
Jun 13, 2026

Intellia presents Phase 3 results for HAE gene therapy lonvo-z By Investing.com - Investing.com India

Jun 13, 2026
pulisher
Jun 13, 2026

Intellia Therapeutics Says Haleo Met Its Primary Endpoint With An 87% Reduction (P - TradingView

Jun 13, 2026
pulisher
Jun 13, 2026

One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial - Stock Titan

Jun 13, 2026
pulisher
Jun 11, 2026

Intellia Shareholders Back Board, Executive Pay and Auditor - The Globe and Mail

Jun 11, 2026
pulisher
Jun 11, 2026

Exploring High Growth Tech Stocks In The US Market - simplywall.st

Jun 11, 2026
pulisher
Jun 10, 2026

Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bhanji Muna - Moomoo

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia (NTLA) director receives 9,200 RSUs and 13,300 options - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia (NTLA) director Georgia Keresty receives stock awards and options grant - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia Therapeutics (NTLA) director receives stock and option awards - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia (NTLA) director Brian Goff receives RSU and stock option grants - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia (NTLA) director awarded RSUs and stock options in new grant - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia Therapeutics (NTLA) posts 2026 shareholder voting results - Stock Titan

Jun 10, 2026
pulisher
Jun 10, 2026

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Singapore

Jun 10, 2026
pulisher
Jun 09, 2026

Draft FDA guidance could be a boon for gene therapy developers - MSN

Jun 09, 2026
pulisher
Jun 09, 2026

Intellia Therapeutics Stock Short Interest Rises to 46.78% - Quiver Quantitative

Jun 09, 2026
pulisher
Jun 09, 2026

Intellia Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 09, 2026
pulisher
Jun 06, 2026

Intellia Therapeutics, Inc. Trade Ideas — XETR:38I - TradingView

Jun 06, 2026
pulisher
Jun 06, 2026

Average basic shares outstanding of Intellia Therapeutics, Inc. – XETR:38I - TradingView

Jun 06, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Intellia Therapeutics Inc (NTLA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Clark Eliana
EVP, Chief Technical Officer
Mar 02 '26
Sale
13.78
607
8,364
93,864
LEONARD JOHN M
President and CEO
Jan 05 '26
Sale
9.21
34,146
314,485
1,013,339
Schultes Birgit C
EVP, Chief Scientific Officer
Jan 05 '26
Sale
9.21
8,508
78,359
98,533
BASTA JAMES
EVP, General Counsel
Jan 05 '26
Sale
9.21
10,397
95,756
101,528
Cohen Fred E
Director
Jan 05 '26
Buy
9.35
150,000
1,402,500
207,453
Lebwohl David
EVP, Chief Medical Officer
Jan 05 '26
Sale
9.21
11,903
109,627
121,249
Clark Eliana
EVP, Chief Technical Officer
Jan 05 '26
Sale
9.21
9,515
87,633
87,118
Dulac Edward J III
EVP, Chief Financial Officer
Jan 05 '26
Sale
9.21
6,379
58,751
99,683
Dube Michael P
VP, Chief Accounting Officer
Jan 05 '26
Sale
9.21
2,989
27,529
52,277
LEONARD JOHN M
President and CEO
Dec 11 '25
Option Exercise
6.83
49,959
341,220
1,127,074
$30.41
price up icon 1.27%
$55.40
price up icon 6.27%
$89.50
price down icon 1.43%
$54.21
price down icon 0.11%
ONC ONC
$263.92
price down icon 1.60%
$156.58
price down icon 2.17%
大文字化:     |  ボリューム (24 時間):